Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare
Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/
From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)
The Hive builds on Almirall's open innovation centre, which began operations in 2023 with collaborations with two life science companies. The arrival of two new joiners announced today contribute to the creation of this unique collaboration ecosystem, following the initial partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products.
The initiative was launched today as part of Almirall's 80th anniversary celebrations, bringing together health authorities, representatives from associations, entities, and institutions with whom Almirall closely collaborates to deliver against its commitment to patients, innovation, and the advancement of healthcare. The new joiners at The Hive include ADmit Therapeutics a company focused on the early detection of Alzheimer’s and other neurodegenerative diseases through technology that combines epigenetic and clinical data using machine learning. The most recent addition is Microomics a company specializing in metagenomic analysis using new DNA sequencing technologies (NGS).
"At Almirall, we bring together scientific experts from different disciplines in a collaborative environment as we see the transformative power collaboration has to push the boundaries of science and drive the development of novel solutions. An open innovation ecosystem that fosters this collaboration lays an exceptional foundation for breakthroughs in both scientific discovery and product development. We are proud to lead the way with The Hive, a unique initiative designed to advance science and innovation. By working together, we can address critical unmet needs and deliver meaningful progress in healthcare, ensuring that our innovations make a tangible difference in the lives of patients and their families", stated Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer.
80 years of innovation and commitment to patients
Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, María José Alonso, professor of Pharmacy and Pharmaceutical Technology at the University of Santiago de Compostela (USC), and Lourdes Borrell, Mayor of Sant Feliu de Llobregat.
Professor María José Alonso congratulated Almirall for its 80 decades “preserving the value of science and its transfer to industry in the best way, contributing to development and well-being, and elevating scientific value in the development of the Spanish innovative ecosystem, fostering a brighter future for all”.
Almirall was founded in Spain in 1944 with the purpose of giving people access to impactful medicines, a goal that continues to guide the company in its ambition as a leading medical dermatology. Almirall´s heritage, its deep scientific expertise, and the strong partnerships with the dermatology community worldwide are the foundation for its broad portfolio of dermatological treatments. Grounded in science and driven by innovation, the company continuously advances the understanding of skin diseases and provides solutions for even the most complex conditions. Based on this dedication, Almirall has become a leader in medical dermatology in Europe, with a strong portfolio of more than 50 products across different modalities, including topical, systemic, and biologics.
The company has invested 1 billion Euros in R&D in medical dermatology in the last decade which represents a continuous investment of over 12% of its annual net sales in R&D. This investment supports all phases of research conducted at its R&D centre – from discovery to late-stage clinical testing. Almirall’s close partnership with patients and dermatologists positions the company as a trusted and reliable partner, as it constantly focuses on understanding their needs to translate these into innovative solutions, helping improve people's lives both physically and emotionally.
Carlos Gallardo, Chairman and CEO of Almirall: "Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our journey has been driven by a profound dedication to improving patients' lives and providing meaningful treatments. As a family-owned company, we think in generations, and have consistently prioritized innovation in medical dermatology, investing over 1 billion Euros in R&D in this area over the last decade. We are grateful for the dedication of our teams across the company, and our partners and collaborators that enable us to help so many patients, every day. Our leading capabilities in skin biology and product development will continue to be a cornerstone of our mission, ensuring our sustained focus on science and innovation to deliver healthcare solutions to patients and the medical community."
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit https://www.almirall.com/
Legal notice:
This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204100180/en/
Contacts
Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173
Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
APRIL Group Continues Its International Expansion by Strengthening Its Presence in China5.12.2024 19:02:00 CET | Press Release
APRIL Group is taking a further step forward in its growth by strengthening its presence in Shanghai and across the pan-Asian region to offer its health insurance solutions to people living locally or abroad. APRIL is thus stepping up its international expansion, following the opening in recent months of offices in Dubai in the Middle East and Cologne in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205885654/en/ (Photo: Business Wire) By enhancing its presence in China, the group is solidifying its footprint in Asia, where it now operates in 7 markets (China, Hong Kong, Indonesia, Singapore, Thailand, Vietnam and the Philippines). APRIL International supports individuals and companies in all their international mobility projects, as well as high net worth individuals who benefit from high-quality local healthcare networks. To further develop its presence in China, APRIL international has chosen to draw on the e
Aktana Announces First-To-Market GenAI Agents That Survive CRM Transitions5.12.2024 16:00:00 CET | Press Release
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the Aktana Action Agent - designed to empower field teams and future-proof omnichannel engagement. “The major players in Life Sciences CRM systems and Customer Data Platforms (CDPs) are changing roadmaps and partnerships, leaving pharma companies facing a serious innovation challenge.” said Derek Choy, Co-founder and Chief Product Officer of Aktana. “There’s an urgent need to help leaders find future-proofed solutions that address today’s business needs, as they confront expensive migration decisions in this shifting landscape.” Aktana was recently named a Leader and one of only three Star Performers in the 2024 Life Sciences Next-Generation Customer Engagement Platform (CEP) PEAK Matrix® by Everest Group, cementing Aktana's position as a leading future-proof CEP. “Life Sciences enterprises are increasingly prioritizing experience-driven Customer Engagement Platforms over
Rigaku Announces XSPA-200 ER Detector for X-ray Diffraction System5.12.2024 16:00:00 CET | Press Release
Rigaku Corporation (headquarters: Akishima City, Tokyo; president and CEO: Jun Kawakami; hereinafter “Rigaku”), a Rigaku Holdings Group company and global solution partner in X-ray analytical devices, began receiving orders for the XSPA-200 ER, an X-ray seamless pixel array detector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204768796/en/ XSPA-200 ER mounted on a MiniFlex (Photo: Business Wire) The XSPA-200 ER uses high energy resolution to defeat increases in background noise from samples. In this way, the XSPA-200 ER enables high-sensitivity measurement even in samples containing transition metals*, such as materials in steel and batteries. Formerly, such measurements required large X-ray analytical equipment; with the arrival of the XSPA-200 ER, the analysis can be performed using desktop X-ray analyzers such as the MiniFlex. The XSPA-200 ER makes high-precision X-ray analysis easier than ever. Expected benefits i
Americhem Unveils 2024 Sustainability Report Highlighting Major Accomplishments5.12.2024 16:00:00 CET | Press Release
Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, proudly announces the release of its 2024 Sustainability Report. This comprehensive report, titled Embracing Our Tomorrow, highlights Americhem’s unwavering commitment to environmental and social responsibility, providing an in-depth look at the company’s efforts across the entire value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205637181/en/ Lauren Lutikoff, Americhem Global Sustainability Leader (Photo: Business Wire) Following the recent award of the Silver EcoVadis Medal, which places Americhem among the top 15% of companies assessed by EcoVadis—a globally recognized platform that rates businesses’ sustainability in various categories including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. Americhem’s sustainabilit
AMP Raises $91 Million in Series D Funding to Revolutionize Waste5.12.2024 15:00:00 CET | Press Release
AMP Robotics Corp. (“AMP”), a leading provider of AI-powered sortation at scale for the waste and recycling industry, has raised $91 million in corporate equity in a Series D financing led by Congruent Ventures. The round featured participation from current and new investors, including Sequoia Capital, XN, Blue Earth Capital, Liberty Mutual Investments, California State Teachers Retirement System (CalSTRS), Wellington Management, Range Ventures, and Tao Capital Partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205769962/en/ AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually. (Photo: Business Wire) AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems, which are capabl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom